AB
AEON BiopharmaClinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA), a biosimilar to Botox, for therapeutic indications like cervical dystonia and chronic migraine.
1 Pulse story
CT
Celea TherapeuticsClinical-stage biotech developing deupirfenidone, a deuterated pirfenidone-derived drug for idiopathic pulmonary fibrosis, spun out of PureTech Health.
4 Pulse stories
Total Raised
$180M
AEON BiopharmaCelea Therapeutics
Last ValuationNot disclosed
Biotech
Sector
Biotech
2013
Founded
2025
Irvine, California
HQ
Boston, MA
Public (AEON)
Status
Private
AEON Biopharma investors
No investors on record.
Celea Therapeutics investors
RA Capital ManagementLeaps by BayerPureTech Health
Data from Value Add Pulse coverage and company research — see the full threads for AEON Biopharma and Celea Therapeutics.